BeiGene, Ltd. (NASDAQ:BGNE) Receives $253.69 Consensus Price Target from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $253.69.

Several equities research analysts recently commented on the stock. JMP Securities started coverage on shares of BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. StockNews.com cut shares of BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JPMorgan Chase & Co. upped their target price on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Finally, TD Cowen raised their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

BeiGene Price Performance

BGNE stock opened at $181.89 on Wednesday. The firm has a 50 day moving average of $197.82 and a 200-day moving average of $188.23. The company has a market cap of $17.74 billion, a price-to-earnings ratio of -22.07 and a beta of 0.57. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. BeiGene has a 12-month low of $126.97 and a 12-month high of $248.16.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.01 earnings per share. As a group, equities analysts expect that BeiGene will post -5.64 EPS for the current fiscal year.

Insider Activity

In other BeiGene news, insider Xiaodong Wang sold 41,760 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $186.90, for a total transaction of $7,804,944.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Chan Henry Lee sold 1,202 shares of BeiGene stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. Insiders sold a total of 1,126,622 shares of company stock valued at $211,419,037 over the last quarter. Company insiders own 7.43% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Blue Trust Inc. increased its position in shares of BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in BeiGene during the 3rd quarter worth $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BeiGene in the 3rd quarter valued at $67,000. SG Americas Securities LLC acquired a new stake in BeiGene in the 3rd quarter valued at $105,000. Finally, PFG Investments LLC purchased a new position in BeiGene in the third quarter valued at about $210,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.